201 related articles for article (PubMed ID: 36104427)
21. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
[TBL] [Abstract][Full Text] [Related]
22. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
23. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.
Fu J; Jia Q; Zhou H; Zhang L; Wang S; Liang P; Lv Y; Han S
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122469. PubMed ID: 33310480
[TBL] [Abstract][Full Text] [Related]
24. Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
Hu Y; Liu L; Lu X
Front Endocrinol (Lausanne); 2021; 12():725967. PubMed ID: 34745001
[TBL] [Abstract][Full Text] [Related]
25. ACE2 Shedding and the Role in COVID-19.
Wang J; Zhao H; An Y
Front Cell Infect Microbiol; 2021; 11():789180. PubMed ID: 35096642
[TBL] [Abstract][Full Text] [Related]
26. The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review.
Chen L; Chen H; Dong S; Huang W; Chen L; Wei Y; Shi L; Li J; Zhu F; Zhu Z; Wang Y; Lv X; Yu X; Li H; Wei W; Zhang K; Zhu L; Qu C; Hong J; Hu C; Dong J; Qi R; Lu D; Wang H; Peng S; Hao G
Function (Oxf); 2020; 1(2):zqaa012. PubMed ID: 38626250
[TBL] [Abstract][Full Text] [Related]
27. GMI, a protein from Ganoderma microsporum, induces ACE2 degradation to alleviate infection of SARS-CoV-2 Spike-pseudotyped virus.
Yeh H; Vo DNK; Lin ZH; Ho HPT; Hua WJ; Qiu WL; Tsai MH; Lin TY
Phytomedicine; 2022 Aug; 103():154215. PubMed ID: 35691077
[TBL] [Abstract][Full Text] [Related]
28. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Aweeka F; Luetkemeyer AF; Savic RM
Clin Pharmacol Ther; 2020 Aug; 108(2):253-263. PubMed ID: 32285930
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
30. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
[TBL] [Abstract][Full Text] [Related]
31. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
32. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
Gasmi A; Peana M; Noor S; Lysiuk R; Menzel A; Gasmi Benahmed A; Bjørklund G
Appl Microbiol Biotechnol; 2021 Feb; 105(4):1333-1343. PubMed ID: 33515285
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
34. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].
Troldborg A; Bartels LE; Deleuran B
Ugeskr Laeger; 2020 May; 182(20):. PubMed ID: 32400380
[TBL] [Abstract][Full Text] [Related]
35. Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations.
Paniri A; Hosseini MM; Rasoulinejad A; Akhavan-Niaki H
Eur J Pharmacol; 2020 Nov; 886():173454. PubMed ID: 32763298
[TBL] [Abstract][Full Text] [Related]
36. Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants.
Dehghani J; Movafeghi A; Mathieu-Rivet E; Mati-Baouche N; Calbo S; Lerouge P; Bardor M
Mar Drugs; 2022 Oct; 20(11):. PubMed ID: 36354980
[TBL] [Abstract][Full Text] [Related]
37. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Rico-Mesa JS; White A; Anderson AS
Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
[TBL] [Abstract][Full Text] [Related]
39. A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection.
Navya VB; Hosur MV
Inform Med Unlocked; 2021; 26():100714. PubMed ID: 34458558
[TBL] [Abstract][Full Text] [Related]
40. TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2.
Wang Y; Fan Y; Huang Y; Du T; Liu Z; Huang D; Wang Y; Wang N; Zhang P
Cell Signal; 2021 Sep; 85():110064. PubMed ID: 34146659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
